For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The gene discussed is NEFL; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.